1.
Jin X, Sun R, Li Z, Wang X, Xiong X, Lu W, Lyu H, Xiao X, Tian Y, Zhang H, Fang Z, Wang L, Zhao M. CD22-targeted glyco-engineered natural killer cells offer a further treatment option for B-cell acute lymphoblastic leukemia. Haematologica 2024;109(9):3004-3008; https://doi.org/10.3324/haematol.2023.284241.